Gaia puts a price on uncertainty

By the fourth unsuccessful IVF attempt, Nader AlSalim had acquired an education he never wanted. He and his wife had crossed borders, changed clinics, and kept going. They conceived on the fifth attempt. In his early account of the journey, the bill was roughly £50,000. A man who had spent years analyzing financial risk had become a customer unable to establish the eventual price of what he was buying.

That mismatch became Gaia. Founded in 2019, the company sits between the clinic, the patient, and the money. Its proposition is easy to grasp: establish the treatment price, include protection against particular setbacks, and give people someone to call. The harder part is making that promise survive contact with biology.

The invoice kept getting another chapter

AlSalim’s realization grew out of repetition. In his own telling, another attempt brought another expectation that this time would work. He wanted a roadmap and a total budget. Neither arrived. His investor interview describes a company that began as a list of patients’ questions, followed by his departure from a 14-year investment-banking career.

There is a useful distinction here. An expensive procedure has a price. An uncertain sequence of expensive procedures has a financial plot twist. Gaia addresses the second problem. Its expertise combines fertility data, financial risk, clinic relationships, and patient coordination. Each piece makes the others more useful: a prediction can inform a price; a clinic agreement can turn that price into an actual treatment plan.

One price, with the important bits spelled out

Today’s U.S. offer centers on IVF, egg freezing, and frozen embryo transfers. Customers choose a partner clinic, meet their doctor, and get a Gaia quote based on the treatment protocol. They can pay upfront or apply to spread payments. Gaia handles the provider bills, including core items such as anesthesia, monitoring, and storage that can otherwise appear separately.

Its homepage uses $20,000 as a representative IVF price and says the actual quote varies by clinic and treatment route. That is a starting illustration for a comparison, not a universal tariff. Interest and optional extras deserve separate attention.

The protections deserve slower reading than the slogan. Gaia’s current FAQs describe a second retrieval without another charge if the first produces no viable embryos, plus unlimited embryo transfers within the plan year. Medication and embryo genetic testing can be added at fixed cost. Those details define the purchase: a retrieval and a transfer are different events, and a year has an ending.

Egg freezing makes the distinction between a promise and a hope especially clear. Gaia advertises a guarantee option for eligible people under 38 with an AMH level above 1.25: at least seven mature eggs, with up to two cycles and a refund provision. The target is a count of eggs. It cannot establish whether those eggs will eventually produce a child.

The offer also includes a dedicated advocate, an independent nurse consultation, a therapy session, and nutritional guidance. These services help explain why Gaia presents itself as a care company as well as a financing business. Someone still has to translate the paperwork when the customer is tired, worried, and thinking about something much bigger than paperwork.

A forecast needs money behind it

Gaia’s early prediction tool was called Gabi. In a 2021 interview, AlSalim described using patient information and historical clinical data to personalize forecasts and insured financial plans. He was also explicit about the limits of prediction: it could offer guidance, never certainty.

“Nothing is going to be 100% accurate when it comes to predicting outcomes.”

Nader AlSalim · Erevena interview, 2021

The useful business idea is attaching a financial commitment to the forecast. An estimate alone leaves the patient holding the bill if events go differently. A defined protection makes Gaia responsible for specified costs. That responsibility needs pricing discipline, enough data to assess risk, and capital available when members need more care than expected.

In May 2026, Gaia announced a $100 million debt facility from Viola Credit. That is credit capacity, distinct from the $37 million of equity funding reported at the time. Earlier rounds included $20 million led by Atomico in 2022 and a $14 million Valar-led investment announced in January 2025. The distinction matters whenever a company must fund care before collecting all its payments.

The clinic gets a simpler bargain, too

Gaia’s provider pitch is concrete: clinics get paid for services while Gaia carries the financial risk it has agreed to take. The clinic-facing site says it also takes the repayment risk. That arrangement gives a financial coordinator a reason to introduce Gaia when a patient hesitates over costs.

Distribution follows those conversations. IVI RMA North America announced a partnership in June 2025; GIVF Fertility followed in June 2026. Alternatives include fertility lenders such as CapexMD and PatientFi, Future Family’s financing and insurance offerings, and clinic refund programs. The sensible comparison includes treatment scope, protections, eligibility, and total credit cost. A monthly payment alone tells a remarkably incomplete story.

A smaller map, a clearer proposition

Gaia’s recent history includes a retreat. Its UK closure notice says new treatment-coverage quotes ended on April 7, 2026; its homepage promises continued support for existing members. Its live employer page also currently puts new partners on a waitlist. The consumer story is now chiefly American.

For customers, the boundaries are practical. Gaia says its plans suit out-of-pocket or partially insured patients; comprehensive insurance may make them unnecessary. Consumer plans currently exclude surrogacy. Consultation and diagnostics sit outside coverage, and financing requires credit approval. The signed quote, including optional extras and timing, matters more than a representative advertised price.

Other businesses can copy the underlying discipline: identify a costly uncertainty, write down exactly what protection means, and fund the obligation. For a family weighing another attempt, that discipline has a less abstract purpose. It makes the next financial decision easier to see while the outcome remains unknown.